Drug Trial Radar · NCT07118878
A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 6, 2025
Primary completion
Sep 15, 2025
Study completion Sep 15, 2025
Sponsor
- Lead sponsor
- Agomab Spain S.L.U.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical intervention. There are currently no approved therapies for treating fibrostenotic Crohn's disease (FSCD) and therefore, there is an urgent need for safe and effective antifibrotic therapies. AGMB-129 has shown to be safe in healthy participants with single doses up to 1200 mg and multiple doses up to 200 mg twice daily (BID) for 10 days, and in FSCD patients with multiple doses up to 200 mg BID for 12 weeks. This Phase 1 study will explore the safety, tolerability, and pharmacokinetics (PK) of other daily doses of AGMB-129 in healthy participants to inform on dose selection (nominal dose and dosing frequency) for subsequent clinical trials.
Conditions
- Fibrostenotic Crohn's Disease
Interventions
AGMB-129Drug
AGMB-129
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participant with Adverse EventsTime frame: From enrollment to the end of treatment at 42 days
- Number of participant with abnormal Physical examinationTime frame: From enrollment to the end of treatment at 42 days
- Number of participant with abnormal Vital signsTime frame: From enrollment to the end of treatment at 42 days
- Number of participant with abnormal electrocardiograms (ECGs) parametersTime frame: From enrollment to the end of treatment at 42 days
- Number of participant with abnormal 2-dimensional (2-D) echocardiographyTime frame: From enrollment to the end of treatment at 42 days
- Number of participant with abnormal clinical laboratory testsTime frame: From enrollment to the end of treatment at 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Belgium
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.